264 related articles for article (PubMed ID: 29849166)
21. Tear osmolarity, dry eye syndrome, blepharospasm and botulinum neurotoxin.
Girard B; de Saint Sauveur G
J Fr Ophtalmol; 2021 Dec; 44(10):1553-1559. PubMed ID: 34756743
[TBL] [Abstract][Full Text] [Related]
22. Comparison of techniques of botulinum toxin injections for blepharospasm and hemifacial spasm.
Sacramento DRC; Lima A; Maia DP; Cunningham M; Maciel RH; Camargos ST; Cardoso F
Mov Disord; 2019 Sep; 34(9):1401-1403. PubMed ID: 31251420
[No Abstract] [Full Text] [Related]
23. The effect of botulinum toxin a treatment on tear function parameters and on the ocular surface.
Horwath-Winter J; Berglöff J; Flögel I; Haller-Schober EM; Müllner K; Schmut O
Adv Exp Med Biol; 2002; 506(Pt B):1241-6. PubMed ID: 12614060
[No Abstract] [Full Text] [Related]
24. Outcome of Injection Botulinum Toxin in Blepharospasm.
Amatya M; Limbu B; Sthapit PR; Gurung HB; Saiju R
Nepal J Ophthalmol; 2021 Jan; 13(25):40-49. PubMed ID: 33981096
[TBL] [Abstract][Full Text] [Related]
25. Changes in ocular higher-order aberrations following botulinum toxin treatment in patients with blepharospasm : BTX improves dry eye in patients with BEB.
Isshiki Y; Ishikawa H; Mimura O
Jpn J Ophthalmol; 2016 Nov; 60(6):486-491. PubMed ID: 27503401
[TBL] [Abstract][Full Text] [Related]
26. Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm.
Cakmur R; Ozturk V; Uzunel F; Donmez B; Idiman F
J Neurol; 2002 Jan; 249(1):64-8. PubMed ID: 11954870
[TBL] [Abstract][Full Text] [Related]
27. A patient-initiated treatment model for blepharospasm and hemifacial spasm: a randomized controlled trial.
Lawes-Wickwar S; McBain H; Brini S; Hirani SP; Hurt CS; Flood C; Dunlop N; Solly D; Crampton B; Newman SP; Ezra DG
BMC Neurol; 2022 Mar; 22(1):99. PubMed ID: 35300599
[TBL] [Abstract][Full Text] [Related]
28. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye.
Horwath-Winter J; Bergloeff J; Floegel I; Haller-Schober EM; Schmut O
Br J Ophthalmol; 2003 Jan; 87(1):54-6. PubMed ID: 12488263
[TBL] [Abstract][Full Text] [Related]
29. Comparison of two different formulations of botulinum toxin A for the treatment of blepharospasm and hemifacial spasm.
Wu CJ; Shen JH; Chen Y; Lian YJ
Turk Neurosurg; 2011; 21(4):625-9. PubMed ID: 22194126
[TBL] [Abstract][Full Text] [Related]
30. Blinking Parameters Do Not Normalize After Botulinum Toxin Therapy in Blepharospasm and Hemifacial Spasm Patients.
Gameiro GR; Osaki MH; Yabumoto C; Osaki T; Garcia DM; Belfort R; Cruz AAV; Osaki TH
J Neuroophthalmol; 2023 Dec; 43(4):563-568. PubMed ID: 37307066
[TBL] [Abstract][Full Text] [Related]
31. [Changes in dose and injection pattern in the botulinum toxin long-term therapy of facial dyskinesis].
Laskawi R; Niemczewska A; Schneider S; Winterhoff J; Beutner C; Rohrbach S
Laryngorhinootologie; 2014 Mar; 93(3):186-92. PubMed ID: 24323508
[TBL] [Abstract][Full Text] [Related]
32. Pain relief in patients receiving periocular botulinum toxin A.
Harrison AR; Erickson JP; Anderson JS; Lee MS
Ophthalmic Plast Reconstr Surg; 2008; 24(2):113-6. PubMed ID: 18356715
[TBL] [Abstract][Full Text] [Related]
33. An objective tool to measure the effect of botulinum toxin in blepharospasm and hemifacial spasm.
Osaki MH; Osaki TH; Garcia DM; Osaki T; Gameiro G; Belfort R; Cruz AAV
Eur J Neurol; 2020 Aug; 27(8):1487-1492. PubMed ID: 32294304
[TBL] [Abstract][Full Text] [Related]
34. Riolan's muscle: action and indications for botulinum toxin injection.
Mackie IA
Eye (Lond); 2000 Jun; 14 ( Pt 3A)():347-52. PubMed ID: 11026998
[TBL] [Abstract][Full Text] [Related]
35. Lid wiper epitheliopathy in patients with blepharospasm and/or hemifacial spasm.
Romero-Caballero MD; Salmerón Ato MP; Palazón-Cabanes A; Caravaca-Alegría A
Arch Soc Esp Oftalmol (Engl Ed); 2022 Jul; 97(7):376-380. PubMed ID: 35292220
[TBL] [Abstract][Full Text] [Related]
36. Long-term efficacy of botulinum a toxin for blepharospasm and hemifacial spasm.
Gill HS; Kraft SP
Can J Neurol Sci; 2010 Sep; 37(5):631-6. PubMed ID: 21059510
[TBL] [Abstract][Full Text] [Related]
37. A direct comparison of onabotulinumtoxina (Botox) and IncobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique.
Saad J; Gourdeau A
J Neuroophthalmol; 2014 Sep; 34(3):233-6. PubMed ID: 24739994
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes of individualized botulinum neurotoxin type A injection techniques in patients with essential blepharospasm.
Sung Y; Nam SM; Lew H
Korean J Ophthalmol; 2015 Apr; 29(2):115-20. PubMed ID: 25829828
[TBL] [Abstract][Full Text] [Related]
39. Quality of life in hemifacial spasm patient after treatment with botulinum toxin A; a 24-week, double-blind, randomized, cross-over comparison of Dysport and Neuronox study.
Kongsengdao S; Kritalukkul S
J Med Assoc Thai; 2012 Mar; 95 Suppl 3():S48-54. PubMed ID: 22619887
[TBL] [Abstract][Full Text] [Related]
40. Effects of the periocular botulinum toxin on the ocular surface and anterior chamber: a prospective study in patients with hemifacial spasm and blepharospasm.
Romero-Caballero MD; Miralles de Imperial-Ollero JA; Sarabia-Marín E; Villegas-Pérez MP
Int Ophthalmol; 2023 Aug; 43(8):2731-2736. PubMed ID: 37185774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
